Early ¹⁸F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis

¹ Department of Radiology, H. Mondor Hospital, AP-HP/Paris 12 University, Créteil, France
² Department of Nuclear Medicine, H. Mondor Hospital, AP-HP/Paris 12 University, Créteil, France
³ Department of Hematology, H. Mondor Hospital, AP-HP/Paris 12 University, Créteil, France
⁴ Department of Nuclear Medicine, Tenon Hospital, AP-HP/Paris 6 University, Paris, France

^* To whom correspondence should be addressed. E-mail: michel.meignan{at}hmn.aphp.fr.

	Abstract

The purpose of this study was to assess the prognostic value of early ¹⁸F-FDG PET using standardized uptake value (SUV) compared with visual analysis in patients with diffuse large B-cell lymphoma (DLBCL). Methods: Ninety-two patients with newly diagnosed DLBCL underwent ¹⁸F-FDG PET prospectively before and after 2 cycles of chemotherapy (at midtherapy). Maximum SUV (SUVmax) and mean SUV (SUVmean) normalized to body weight and body surface area, as well as tumor-to-normal ratios, were computed on the most intense uptake areas. The SUVs, tumor-to-normal ratios, and their changes over time were compared with visual analysis for predicting event-free survival (EFS) and overall survival, using receiver-operating-characteristic (ROC) analysis. Survival curves were estimated with Kaplan–Meier analysis and compared using the log-rank test. Results: With visual analysis, the accuracy of early PET to predict EFS was 65.2%. The 2-y estimate for EFS was 51% (95% confidence interval [CI], 34%–68%) in the PET-positive group compared with 79% (95% CI, 68%–90%) in the PET-negative group (P = 0.009). An optimal cutoff value of 65.7% SUVmax reduction from baseline to midtherapy obtained from ROC analysis yielded an accuracy of 76.1% to predict EFS. The 2-y estimate for EFS was 21% (95% CI, 0%–42%) in patients with SUVmax reduction 65.7% compared with 79% (95% CI, 69%–88%) in those with reduction > 65.7% (P < 0.0001). Fourteen patients considered as positive on visual analysis could have been reclassified as good responders. Conclusion: SUV-based assessment of therapeutic response during first-line chemotherapy improves the prognostic value of early ¹⁸F-FDG PET compared with visual analysis in DLBCL.

Key Words: early PET, standardized uptake value, lymphoma, prognosis, response

This article has been cited by other articles:

				S. J. Horning, M. E. Juweid, H. Schoder, G. Wiseman, A. McMillan, L. J. Swinnen, R. Advani, R. Gascoyne, and A. Quon Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study Blood, January 28, 2010; 115(4): 775 - 777. [Abstract] [Full Text] [PDF]

				M. Weiler-Sagie, O. Bushelev, R. Epelbaum, E. J. Dann, N. Haim, I. Avivi, A. Ben-Barak, Y. Ben-Arie, R. Bar-Shalom, and O. Israel 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients J. Nucl. Med., January 1, 2010; 51(1): 25 - 30. [Abstract] [Full Text] [PDF]

				F. M. Paes, D. G. Kalkanis, P. A. Sideras, and A. N. Serafini FDG PET/CT of Extranodal Involvement in Non-Hodgkin Lymphoma and Hodgkin Disease RadioGraphics, January 1, 2010; 30(1): 269 - 291. [Abstract] [Full Text] [PDF]

				P. Xie, J.-B. Yue, Z. Fu, R. Feng, and J.-M. Yu Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma Ann. Onc., November 13, 2009; (2009) mdp430v1. [Abstract] [Full Text] [PDF]

				L. M. Velasquez, R. Boellaard, G. Kollia, W. Hayes, O. S. Hoekstra, A. A. Lammertsma, and S. M. Galbraith Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies J. Nucl. Med., October 1, 2009; 50(10): 1646 - 1654. [Abstract] [Full Text] [PDF]

				D. Delbeke, S. Stroobants, E. de Kerviler, C. Gisselbrecht, M. Meignan, and P. S. Conti Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma Oncologist, October 1, 2009; 14(suppl_2): 30 - 40. [Abstract] [Full Text] [PDF]

				M. Meignan, E. Itti, S. Bardet, J. Lumbroso, V. Edeline, P. Olivier, T. V. Borght, O. Reman, G. Karcher, O. Mundler, et al. Development and Application of a Real-Time On-Line Blinded Independent Central Review of Interim Pet Scans to Determine Treatment Allocation in Lymphoma Trials J. Clin. Oncol., June 1, 2009; 27(16): 2739 - 2741. [Full Text] [PDF]

				R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]

				E. Itti, C. Lin, J. Dupuis, G. Paone, D. Capacchione, A. Rahmouni, C. Haioun, and M. Meignan Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy J. Nucl. Med., April 1, 2009; 50(4): 527 - 533. [Abstract] [Full Text] [PDF]

				J. Dupuis, E. Itti, A. Rahmouni, F. Hemery, C. Gisselbrecht, C. Lin, C. Copie-Bergman, K. Belhadj, T. El Gnaoui, I. Gaillard, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria Ann. Onc., March 1, 2009; 20(3): 503 - 507. [Abstract] [Full Text] [PDF]

				S. Ben-Haim and P. Ell 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response J. Nucl. Med., January 1, 2009; 50(1): 88 - 99. [Abstract] [Full Text] [PDF]

				H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy J. Nucl. Med., January 1, 2009; 50(1): 8 - 17. [Abstract] [Full Text] [PDF]

				M. R. Benz, V. Evilevitch, M. S. Allen-Auerbach, F. C. Eilber, M. E. Phelps, J. Czernin, and W. A. Weber Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors J. Nucl. Med., July 1, 2008; 49(7): 1038 - 1046. [Abstract] [Full Text] [PDF]

				W. A. Weber 18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative? J. Nucl. Med., October 1, 2007; 48(10): 1580 - 1582. [Full Text] [PDF]